Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Nature Communications 2026 Open access

Read full text
Authors: Keun‐Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, Inho Kim, Do-Youn Oh, Hope Elizabeth Uronis, Sun Jin Sym, Mohamad Bassam Sonbol, Khaldoun Almhanna, Mohamedtaki Abdulaziz Tejani, Beodeul Kang, Michael H. Kagey
+6 more Melissa C Stilian, Calvin Jia, Cynthia A. Sirard, Rachel A. Altura, Jaffer A. Ajani, Samuel Jacob Klempner
DOI: 10.1038/s41467-026-69394-0
Cited by: 0

Abstract

In the version of the article initially published, Rachel Altura was missing from the author list and has now been added to the HTML and PDF versions of the article.

Fields of Study & Subjects

Gastric Cancer Management and Outcomes Esophageal Cancer Research and Treatment Cancer Immunotherapy and Biomarkers

Publication details

Journal / source
Nature Communications
Volume
17
Issue
1
Pages
1437–1437
Publication date
6 February 2026
Language
EN